Batten disease is inherited disorder of the nervous system which begins in childhood. It is also called as neuronal ceroid lipofuscinoses (or NCLs). According to Batten Disease Support and Research Association, four out of every 1,000 are prone to batten disease in U.S. Mostly batten disease are common in Finland, other parts of Northern Europe, North America and Sweden. Till date, there is no treatment available for stopping or reversing the symptoms of batten disease but there are few tests such as urine test or blood test, tissue sampling, measurement of enzyme activity, diagnostic imaging using magnetic resonance imaging (MRI) or computed tomography (CT). As there is huge potential in this industry many companies are vying to plunge into this untapped market by providing solutions for treatment of batten disease. For instance, disease CLN2 Disease, therapeutic BMN 190, recombinant human tripeptidyl peptidase-1 (rhTPP1), molecule of BioMarin is currently in phase III clinical trials.